Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Medtronic introduces app-based remote monitoring system for pacemakers in US
Medtronic plc announced US Food and Drug Administration (FDA) approval and US commercial availability of the MyCareLink Smart Monitor, the world's first app-based remote monitoring system for patients with implantable pacemakers. With the MyCareLink Smart Monitor, patients with a Medtronic pacemaker can use their own smartphone or tablet technology, with cellular or Wi-Fi service, to securely transmit data from their pacemakers to their physicians, who can then interpret the data to make treatment decisions.
- Read more about FDA approve easy-to-use nasal spray to treat opioid overdose
U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin.
- Read more about India worst affected by TB : US ambassador
US ambassador to India Richard R. Verma on Friday said India is worst effected by tuberculosis (TB) and needs more efforts to fight the disease. Verma said TB was grabbing and finishing India. He said every year 2.2 million people were becoming victim of TB.
- Read more about Google Glass helped to open blocked heart artery
In a world's first, a group of cardiologists has successfully used the eye-wearable device Google Glass to guide the opening up of a chronically blocked right coronary artery in the cardiac cath lab.
- Read more about Diabetes drug may combat fatty liver disease
A drug currently used in the treatment of Type II diabetes can also be effective in clearing fatty liver disease from some patients, a significant research has found.
- Read more about Johnson announces £20 million for Manufacturing Hubs
Two £10 million manufacturing research Hubs that will address major, long-term challenges facing the UK’s manufacturing industries, and capture opportunities from emerging research were announced today by Universities and Science Minister Jo Johnson.

[adsense:336x280:8701650588]
- Read more about Portea Medical acquires MedybizPharma to accelerate penetration into India's chronic disease market
(BWI); Portea Medical, India’s largest home healthcare company, today announced that it has acquired specialty pharmaceutical distributor MedybizPharma in a move that will enable Portea to strengthen patient engagement and provide better care for chronic disease patients in India.
- Read more about Anti-Dengue fogging drive not EF
With over 12,500 dengue cases in Delhi, a green NGO claimed that the ongoing fogging drive in the city was "not effective" in fighting thevector-borne disease, and has rather "harmful" effects on health, as the gas contains "95 per cent" of diesel in it. Saying that fogging only creates a "false" sense of security and is a way of "appeasing" people at the cost of their health, Centre for Science and Environment (CSE) urged the government to focus on systematic preventive measures towards clean environment and sanitation.
- Read more about TESARO launch Varubi in US market
TESARO, Inc., an oncology-focused biopharmaceutical company, announced that VARUBI™ (rolapitant), an NK-1 receptor antagonist, is now available in the United States. The U.S. Food and Drug Administration (FDA) approved VARUBI on Sept. 1, 2015, for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- Read more about Retrophin gets European orphan drug status for Sparsentan to treat FSGS
The European Commission (EC) has granted orphan drug designation to Retrophin Inc's sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).